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A B S T R A C T
Despite slow reductions in the annual burden of active human tuberculosis (TB) cases, zoonotic TB (zTB)
remains a poorly monitored and an important unaddressed global problem. There is a higher incidence in
some regions and countries, especially where close association exists between growing numbers of cattle
(the major source of Mycobacterium bovis) and people, many suffering from poverty, and where dairy
products are consumed unpasteurised. More attention needs to be focused on possible increased zTB
incidence resulting from growth in dairy production globally and increased demand in low income
countries in particular. Evidence of new zoonotic mycobacterial strains in South Asia and Africa (e.g. M.
orygis), warrants urgent assessment of prevalence, potential drivers and risk in order to develop
appropriate interventions. Control of M. bovis infection in cattle through detect and cull policies remain
the mainstay of reducing zTB risk, whilst in certain circumstances animal vaccination is proving
beneficial. New point of care diagnostics will help to detect animal infections and human cases. Given the
high burden of human tuberculosis (caused by M. tuberculosis) in endemic areas, animals are affected by
reverse zoonosis, including multi-drug resistant strains. This, may create drug resistant reservoirs of
infection in animals. Like COVID-19, zTB is evolving in an ever-changing global landscape.
© 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
Introduction
A zoonosis is an infection directly transmissible from animals to
humans naturally (WHO) (WHO, 2020b) and for this to happen
regularly, there needs to be a reservoir in an animal population. The
majority of zoonoses occur where there is close contact between
humans and relatively abundant animal species (Johnson et al.,
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ausing organisms include M. tuberculosissensu stricto and M.
fricanum, causing the majority of human disease. A number of
ther organisms from the M. tuberculosis complex (MTBC), present
n animals and the environment, can cause zTB, these include M.
anetti, M. bovis, M. caprae, M. microti, M. pinnipedii, M. mungi, and
. orygis. Here we provide a contemporary view on the status of
TB globally, emerging trends, research gaps as well as recent
dvances in the agricultural, veterinary and medical sciences
hich can help to re-focus and promote better policy on this
ersistent and still poorly documented disease.
uman TB and the zoonotic contribution
TB is consistently the most impactful bacterial disease to affect
umanity, with a quarter of all humans infected, and is responsible
or the greatest number of infection related deaths, as well as long
erm disability (WHO, 2020c). The 2020 World Health Organiza-
ion (WHO) Global Tuberculosis Report (WHO, 2020a) estimates
hat in 2019, 10 million people (range, 8.9–11.0 million) developed
B disease of which approximately 1.2 million people died, with a
urther 208,000 deaths attributed to the TB-HIV syndemic (WHO,
020a). In addition, effects from the coronavirus disease 2019
COVID-19) pandemic is projected to increase the number of TB
ases by 6.3 million in the next five years or an additional 20%
eaths in next five years (Cilloni et al., 2020; Hogan et al., 2020;
top TB partnership, 2020), delaying the WHO End TB Strategy
WHO, 2014). This is mainly due to reduced case finding, the
eviation of resources to handle the COVID-19 pandemic in
ndemic areas, and the interruption of TB treatment programs in
any low-income countries.
Although TB remains a global challenge, cases are highly
oncentrated in very specific parts of the world, affecting areas
here poverty and high population density overlap. This is not
urprising for an infection that is human density depended linked
o poverty, social stigma, poor public awareness, and overwhelmed
ealth systems lacking resources for TB transmission prevention
nd treatment (Bapat et al., 2017). Nearly 90% of all human TB cases
re located in South Asia, East Asia (China), South East Asia
Philippines, Indonesia) and, the most populous countries in Africa
South Africa and Nigeria, where the addition of HIV-derived
mmunosuppression facilitates the progression of M. tuberculosis
nfection to active TB disease) (WHO, 2020a). A further concern is
ncreasing multi-drug resistant (MDR)-TB, which accounted for
06,030 reported cases (30% of the estimated total) in 2019,
ssociated with an estimated 31,000 deaths (WHO, 2020a).
nimal TB burden
The animal TB burden is highly variable across countries and
ontinents, with main variations according to predominant
ivestock systems. Although the available data may be biased
ue to different sampling strategies and diagnostic capacities, the
ighest animal prevalence is reported from the Americas and
urope (Ramos et al., 2020).
oonotic TB burden
Of 10 million people currently with new active TB, 140,000
range, 69,800–235,000) are estimated to be new cases of zTB
(Ramos et al., 2020) (WHO, 2020a). South-East Asia comprises
almost 44% of the global TB burden (WHO, 2020a). This region
disproportionately shared TB deaths (38% of global burden) (WHO,
2020a).
Although South Asia has the highest burden of TB potentially
related to high rates of poverty, rapid urbanization, high
population density, higher prevalence of diabetes and high air
pollution (Basnyat et al., 2018), the reported burden of zTB is
relatively low. However, this may be partially explained by
insufficient laboratory facilities and lack of accurate identification
of the causative agent of zTB (M. orygis seems to be the major
pathogen in Indian cattle, Bos indicus) (Brites et al., 2018). The
region possesses multiple risk factors for zTB including high
human-animal density, close and frequent physical contact with
infected animals, inadequate disease control measures, as well as
consumption of unpasteurized milk and milk products (Bapat et al.,
2017; Mukherjee et al., 2018). For example India has an estimated
21.8 million (95% CI: 16.6, 28.4) infected cattle in a rapidly growing
dairy sector (Srinivasan et al., 2018)
In contrast, the TB incidence in the European region (WHO
Regional Office for Europe, 2021) is among the lowest in the world
with a consistent decline since 2015 with currently being reported
10 cases per 100,000 population, unevenly distributed across the
European Union/European Economic Area. zTB cases in this region
as a proportion of TB cases is <0.01% (Müller et al., 2013) and most
cases are caused by M. bovis and M. caprae.
Given the limited point of care (POC) diagnostics and poor
reporting there is no reliable data to determine if zTB incidence and
prevalence is going up or down in many regions. Rapid testing
could assist veterinarians and farmers to quickly diagnose TB, so
infected animals can be separated from the rest of the herd.
Current zTB burden and mortality estimates are all based on M.
bovis, the most commonly diagnosed cause of zTB globally, but
essentially ignoring the contribution of other MTBC species.
Emerging evidence suggests that several other mycobacterial
species such as M. orygis are also contributing to zTB (Duffy et al.,
2020), but laboratory services for accurate identification and
speciation are not universally available, thus the true global burden
of zTB is without a doubt much higher.
Past experience directs attention to areas where living
conditions favour direct contact with infected cattle, that may
facilitate aerosol spread, or ingestion of unpasteurised milk
products (e.g. queso fresco). There are rare transmission events
from sheep and goats caused by M.caprae and from non-milk-
producing species such as rodents (M. microti), banded mongooses
(M. mungi), as well as seals and sea lions (M. pinnipedii) with
increasing reports of M. orygis from Indian cattle (Jagielski et al.,
2016; Brites et al., 2018; Duffy et al., 2020).
The detrimental impact of different MTBC species goes beyond
human health, since they also affect the health of cattle and other
animal species with consequential impact on livelihoods, animal-
based industrial food systems, and conservation of wildlife species,
including many iconic species such as bison, rhino’s, lions and even
highly threatened African wild dogs (De Garine-Wichatitsky et al.,
2013; Sichewo et al., 2019; Marais et al., 2019; Luciano and Roess,
2020). The existence of zTB animal carriers adds to the problem
with e.g. deer, buffalo, European badgers, wild boar, brushtail
possums, bison, goats, camelids (including alpaca, llama, camels),
pigs, antelopes, dogs and cats, a number of species implicated in
cases in Europe in addition to the primary reservoir cattle.1.4%) of which an approximately 11,400 (8.1%, range 4,470-21,600)
ied (WHO, 2020a). However, zTB disease is largely underreported
nd, these wide ranges are indicative of major diagnostic
hallenges and poor public health surveillance and reporting
tructures in endemic countries. The highest numbers were
eported from Africa (68,900) and South East Asia (43,400)2
However, incidence and/or risk of transmission of MTBC species
from free-living wildlife species to humans, even among those
with high prevalence such as African buffalo and European
badgers, to-date remains very low (Biet et al., 2005).
Some risk factor surveys have explored the association between
cattle TB prevalence and mixing with wildlife, and prevalence of
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in situations of intense co-grazing and sharing water resources in
Africa and USA. However, the force of infection in these studies and
other examples cited is not conclusive and uncertainties remain on
this question. For example, there are questions on directionality
and rate of transmission between badgers and cattle in TB studies
in the UK (Sandoval Barron et al., 2018). A rare study of this
interface in a mixed system in Uganda showed infection
prevalence rates that were ten times higher in wild buffalo than
in co-grazing cattle (Meunier et al., 2017), suggesting a low
transmission rate from wildlife to cattle.
Reverse zoonoses
Reverse zoonoses or zooanthroponoses have been recorded in
studies from Africa and India (Duffy et al., 2020). Studies in Nigeria
(Adesokan et al., 2019) identified M. bovis in humans and a reverse
zTB transmission from an emerging Uganda I M. tuberculosis strain
between pastoralists and cattle evidenced by MIRU-VNTR. In this
study, 59.2% Uganda I/SIT46 (pastoralists =28; cattle =1), 16.3%
Latin American Mediterranean/SIT61 (pastoralists =8), 2.0% T/
SIT53 (pastoralists =1) had strains of M. tuberculosis and new
strains of M. bovis and M. africanum (Adesokan et al., 2019).
Furthermore, M. tuberculosis has been isolated in a slaughtered
goat in Nigeria and this was attributed to close human-animal
contact in most settings in the country (Cadmus et al., 2009;
Adesokan et al., 2019).
Importantly, an even more troubling possibility in some
settings (particularly where there are poor animal management
and meat inspection coupled with high burden of MDR-TB) is the
prospect of animals serving as a vehicle of transmission for drug
resistant M. tuberculosis as a result of reverse zoonosis at the
human-animal interface (Botelho et al., 2014; Cadmus et al., 2019).
In India, M tuberculosis (MANU strain) was found to be more
prevalent in cattle than M. bovis (Sweetline Anne et al., 2017). M.
tuberculosis MANU1 strain infection in cattle is likely due to
spillover from humans in TB endemic areas (Sweetline Anne et al.,
2017; Mukherjee et al., 2018) and demonstrates the potential for
MDR-TB strains to acquire an animal reservoir that could then pose
a future risk to human TB control. Reverse zoonoses with M.
tuberculosis has also been reported in zoo animals especially in
elephants, primates and felines (Montali et al., 2001). M. orygis
infection has also been recorded in primates in zoo environments,
suggesting shedding from humans or other infected animals.
Molecular studies and diagnostics
M. orygis was first reported as a causative agent of TB in an oryx
(Oryx gazella, Family: Bovidae) (van Ingen et al., 2012), but has since
been identified in many other species as well. These include
African buffalo (Gey van Pittius et al., 2012), in a dairy cow and its
caretaker from New Zealand (Dawson et al., 2012), in free-ranging
rhinoceros (Rhinoceros unicornis) from Nepal (Thapa et al., 2016)
and in 18 cattle from a dairy farm and several rhesus macaque
(Macaca mulatta) in a zoo which died of TB from Bangladesh
(Rahim et al., 2017). In addition, a single case of lymphadenitis
caused by M. orygis was reported from a person in New York, USA
(Marcos et al., 2017).
M. orygis is probably a previously unidentified pathogen of
Indian cattle (Brites et al., 2018), but it seems increasingly
and whole genome sequencing (WGS) for adequate identification
of all MTBC species. Results showed that 97.1% were MTBC, M.
orygis 0.7% and M. bovis BCG 0.5%, none were from wild strains of M.
bovis and only 1.6% nontuberculous Mycobacteria. Twenty-five
isolates were assigned subspecies by WGS as compared with 715
MTBC sequences obtained from the database. The seven M. orygis
isolates from human samples have descended from cattle. This
study presents a convincing case that zTB case definitions should
include human TB caused by M. orygis.
TB in live animals is mainly diagnosed using the intradermal
tuberculin skin test (TST) to detect delayed hypersensitivity
response to tuberculin. Culture or molecular techniques (PCR and
WGS) are used for microbiological confirmation of the TB-causing
agent. Blood tests based on host immune responses (e.g. IFN-ɣ
release assay, ELISA, ELISpot, Differentiating Infected from
Vaccinated Animal [DIVA] test) (Waters et al., 2006; Vordermeier
et al., 2011) are also used for identification of infection with M.
bovis, but its accuracy for diagnosing infection with other zTB
agents has not been established. For all these tests, the
identification of the zTB agent depends on proper collection of
quality specimen. However, these tests are not routinely done in
high burden countries, due to lack of resources and adequately
trained personnel. This is particularly the case for molecular
diagnostics, meaning that TB data often lack the resolution
required for epidemiological studies.
To tackle the diagnosis challenge, we need to learn from current
efforts towards the improvement of human TB diagnosis in the
field. There are efforts to adapt current POC tests used for human
TB to detect potentially zTB organisms in cattle (Kelley et al., 2020)
by investigating the presence of specific and unique MTBC antigens
(biomarkers) in urine, milk and meat juice to quickly identify if an
animal has TB (e.g. Alere DetermineTM Lipoarabinomannan (LAM)
Ag test, SILVAMP TB-LAM (FujiLAM) test). Other tests are based on
detecting the presence of specific antibodies in serum against
unique cell wall components of the MTBC cell wall (e.g. Lionex test,
P22 ELISA). Much work needs to be done to increase the sensitivity
of these tests to detect zTB organisms in animals.
While the research for new and improved tests continues, the
value of the comparative intradermal tuberculin test (CITT) in the
herd diagnosis of TB should not be ignored in settings where the
test is logistically practical to perform. The diagnostic performance
offers a sensitivity and specificity comparable to current blood-
based tests if conducted by well-trained animal health profes-
sionals. The use of the CITT in developing countries has been
largely discontinued because of an erosion of technical expertise in
performing and interpreting the test. The institution of a
harmonised training programme across an endemic region, based
on validated test and interpretation parameters could form a
valuable foundation for the monitoring of the TB status of cattle
populations and would facilitate the validation of new and
improved tests.
Vaccine development
Outcomes of clinical efficacy trials for preventing the develop-
ment of active TB disease in people infected with M. tuberculosis
using the adjuvanted protein subunit vaccine M72/AS01E give
some hope at least for this form of the disease (Schrager et al.,
2020). Historically, eradication of bovine TB from cattle herds by
test-and-slaughter or test-and-cull of infected animals wasimportant as a global pathogen. Isolation of M. orygis from humans
and its apparent prevalence in cattle in South Asia raises a question
as to whether this newly recognized pathogen could be included as
additional causative agent of zTB. In this context, Duffy et al. (2020)
characterized 940 cultures of M. tuberculosis complex from
hospitalized TB patients in India by modified PCR, deletion analysis3
preferred over control by vaccination of cattle. Eradication efforts,
have, however, proven unsuccessful possibly because a wildlife
reservoir is present or where eradication is not affordable or culling
is culturally unacceptable. Oral BCG administration has demon-
strated significant protection against human (Colditz et al., 1995)
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uropean badgers, brushtail possums, wild boar, and deer has
hown to induce protection against TB and could prove to be a
ractical means to vaccinate these species at large scale (Buddle
t al., 2018). This offers a potential solution in settings where “test
nd cull” is not an option and especially in wildlife species
hreatened by extinction. A major constraint of using BCG
accination in cattle is the fact that trading blocs like the European
nion prohibit the use of TB vaccines in cattle, since vaccination
ompromises the interpretation of traditional TB diagnostic tests.
owever, these concerns have been addressed with the develop-
ent of more specific tests that differentiate infected from
accinated animals (DIVA1) (Vordermeier et al., 2011) and of a
iagnostic compatible BCG vaccine strain not eliciting an immune
esponse in the compatible skin test (Chandran et al., 2019).
lthough BCG should offer some protection against multiple MTBC
pecies, including M. orygis, it should be recognized that protection
ill not be complete and should be used to complement, rather
han replace, more traditional control measures.
ocusing attention on zTB emergence
As currently documented, zTB only accounts for around 1.4% of
otal TB (Luciano and Roess, 2020) disease burden in humans,
hich partially explains why it remains a neglected and ‘low
riority’ problem globally, though it may account for about 3% of all
B in Africa. However, the failure of even advanced economies and
ealth systems such as the UK and USA, to eliminate animal TB or
educe risk of zTB to zero in consequence, is concerning. Growing
ncidence of TB and zTB in certain low and middle income
ountries, with risks to their population health and migration to
ther countries, is a stark warning, that failure to control it now,
oses a major risk of future emergence, especially in settings
here disease rates were traditionally low - as the consumption of
ilk and meat rises.
The developing challenge is rooted in demographic drivers and
isks from growing animal-based food systems and the introduc-
ion of so-called ‘improved breeds’ of cattle for dairy into many
ettings, particularly Africa, which are highly susceptible to M.
ovis (Ohlan, 2014). Equally important is the lack of veterinary
ontrol measures and the consumption of unpasteurised milk
roducts. This warrants a review of development and design of
nimal industry and zTB risk factors in these settings. Whilst new
hallenges are emerging and concerns over zTB aired over two
ecades ago, they remain valid today (Olea-Popelka et al., 2017;
umla et al., 2020).
The changing landscape of zTB must be given more political and
cientific attention. This is crucial due to the inherent resistance of
he pathogen to first line medication. zTB is preventable in humans
y effectively controlling the disease in cattle. However, control
easures against the risk of zTB are not universally suitable for
ifferent cattle farming systems or affordable to developing
ations. It should be the responsibility of a multi-disciplinary
ask team taking a One Health approach to identify and evaluate
ontrol measures, which are culturally acceptable as well as
ractical and affordable for veterinary services to implement.
onclusion
Although some progress has been made towards achieving the
rates. Food safety interventions, such as milk pasteurisation, are
the best tool currently to prevent zTB. However, as the use of
unpasteurised dairy products grows globally the incidence of zTB is
predicted to increase, as argued for India.
Better molecular diagnostic tools are enabling more precise
determination of zTB causes, driven by a variety of MTBC species,
the most notable of which is M orygis in South Asia. Given this
changing landscape, there is an urgent need to review the gaps in
the Road Map for Zoonotic TB (WHO, 2017) in order to enhance the
implementation of the 10 priority areas identified by WHO in
earlier statements for tackling zTB in the world.
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